A federal report found that drugmakers, as of Sept. 30, had not begun 1,044 post-market drug studies that they agreed to perform. An industry official said studies can be delayed because of conversations with the agency over their design, as well as difficulty recruiting patients. An FDA spokeswoman said the agency will make sure drug firms finish the incomplete post-approval trials "in a timely manner."

Full Story:

Related Summaries